VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Stock Comparison

Mettler-Toledo International Inc. vs Novo Nordisk A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Mettler-Toledo International Inc.

MTD · New York Stock Exchange

Market cap (USD)
Gross margin (TTM)58.4%
Operating margin (TTM)28.6%
Net margin (TTM)21.2%
SectorHealthcare
CountryUS
Data as of2026-01-01
Moat score
73/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Mettler-Toledo International Inc.'s moat claims, evidence, and risks.

View MTD analysis

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$232.3B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 73 / 100 for Mettler-Toledo International Inc.).
  • Segment focus: Mettler-Toledo International Inc. has 3 segments (56% in Laboratory Products and Services); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: Mettler-Toledo International Inc. has 5 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.

Primary market context

Mettler-Toledo International Inc.

Laboratory Products and Services

Market

Laboratory precision weighing (balances/scales) and adjacent lab measurement & sample-prep instruments, plus related software and services

Geography

Global

Customer

Life science, chemical, academic, and testing laboratories (end-users) via direct sales and distributors

Role

Instrument OEM / software provider / service provider

Revenue share

56%

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Side-by-side metrics

Mettler-Toledo International Inc.
Novo Nordisk A/S
Ticker / Exchange
MTD - New York Stock Exchange
NOVOB - Nasdaq Copenhagen
Market cap (USD)
n/a
$232.3B
Gross margin (TTM)
58.4%
n/a
Operating margin (TTM)
28.6%
n/a
Net margin (TTM)
21.2%
n/a
Sector
Healthcare
Healthcare
HQ country
US
DK
Primary segment
Laboratory Products and Services
Diabetes care
Market structure
Oligopoly
Oligopoly
Market share
25%-30% (estimated)
33.7% (reported)
HHI estimate
2,440
n/a
Pricing power
Strong
Moderate
Moat score
73 / 100
85 / 100
Moat domains
Demand, Supply, Legal
Legal, Supply, Demand
Last update
2026-01-01
2025-12-28

Moat coverage

Shared moat types

Brand Trust

Mettler-Toledo International Inc. strengths

Data Workflow LockinService Field NetworkSwitching Costs GeneralCompliance Advantage

Novo Nordisk A/S strengths

IP Choke PointRegulated Standards PipeCapacity MoatLearning Curve Yield

Segment mix

Mettler-Toledo International Inc. segments

Full profile >

Laboratory Products and Services

Oligopoly

56%

Industrial Products and Services

Competitive

39%

Food Retailing Products and Services

Competitive

5%

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.